Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin’s lymphoma in vitro
Marion Masitsa Malenge(Oslo University Hospital), Jostein Dahle(Oslo University Hospital), Trond Stokke, Marcel Nijland(University Medical Center Groningen), Lydia Visser(University Medical Center Groningen), Sebastian Patzke(Norwegian Cancer Society), Anne Hansen Ree(University of Oslo), Helèn Heyerdahl(Nordic Nanovector (Norway)), Ada H. V. Repetto‐Llamazares(Nordic Nanovector (Norway)), Brian Middleton, Arne Kolstad(Oslo University Hospital), Astri Fjelde Maaland(University of Oslo)
Cited by 3
Related Papers
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523
DISTRIBUTION OF 5‐AMINOLEVULINIC ACID‐INDUCED PORPHYRINS IN NODULOULCERATIVE BASAL CELL CARCINOMA
|Photochemistry and Photobiology|1995|181
Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases
|Blood|2011|178
Genome-Wide Association Study of Classical Hodgkin Lymphoma and Epstein–Barr Virus Status–Defined Subgroups
|JNCI Journal of the National Cancer Institute|2012|171